Lucchesi M, Marchi E, Venturini A P
Chemioterapia. 1984 Dec;3(6):371-2.
The antimycobacterial activity of rifaximin was studied in the guinea pig, after oral administration. The experiment confirmed the scanty absorption of rifaximin in the gastrointestinal tract, as the two dosages used (60 and 30 mg/kg) did not modify the tubercular illness after four months of therapy. Furthermore, sensitivity to rifaximin of the callenging Mycobacterium tuberculosis isolated at the end of the study from the spleen, lung, liver and lymph nodes of the guinea pigs that received rifaximin did not change.
在豚鼠口服给药后，研究了利福昔明的抗分枝杆菌活性。实验证实利福昔明在胃肠道的吸收很少，因为所使用的两种剂量（60和30mg/kg）在治疗四个月后并未改变结核病情。此外，在研究结束时从接受利福昔明治疗的豚鼠的脾脏、肺、肝脏和淋巴结中分离出的致病性结核分枝杆菌对利福昔明的敏感性没有变化。
